...
首页> 外文期刊>Journal of the American Society of Hypertension : >Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension
【24h】

Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension

机译:高血压患者单独或联合使用时血浆肾素活性和醛固酮浓度与对奈必洛尔和缬沙坦的动态血压反应的相关性

获取原文
获取原文并翻译 | 示例
           

摘要

After demonstration of the antihypertensive efficacy of the combination of the beta-blocker nebivolol and the angiotensin receptor blocker valsartan in an 8-week, randomized, placebo-controlled trial (N = 4161), we now report the effects of this treatment on the renin-angiotensin-aldosterone system in a substudy (n = 805). Plasma renin activity increased with valsartan (54%-73%) and decreased with nebivolol (51%-65%) and the combination treatment (17%-39%). Plasma aldosterone decreased with individual treatments (valsartan, 11%-22%; nebivolol, 20%-26%), with the largest reduction (35%) observed with maximum combination dose (20 mg nebivolol/320 mg valsartan). Baseline ln(plasma renin activity) correlated with the 8-week reductions in 24-hour systolic and diastolic BP following treatments with the combination (all doses combined, P = .003 and P < .001) and nebivolol (both, P < .001), but not with valsartan. Baseline ln(aldosterone) correlated with 24-hour systolic and diastolic BP reductions following combination treatment only (P < .001 and P = .005). The implications of the renin-angiotensin-aldosterone system effects of this beta blocker-angiotensin receptor blocker combination should be explored further. (C) 2015 The Authors. Published by Elsevier Inc. on behalf of American Society of Hypertension.
机译:在一项为期8周的随机安慰剂对照试验(N = 4161)中证明了β受体阻滞剂奈比洛尔和血管紧张素受体阻滞剂缬沙坦的联合降压功效后,我们现在报告该治疗对肾素的影响亚研究中的-血管紧张素-醛固酮系统(n = 805)。血浆肾素活性随缬沙坦升高(54%-73%),而奈比洛尔(51%-65%)和联合治疗降低(17%-39%)。血浆醛固酮随单独治疗而降低(缬沙坦,11%-22%;奈必洛尔,20%-26%),最大联合剂量(20 mg奈必洛尔/ 320 mg缬沙坦)观察到最大的减少(35%)。基线ln(血浆肾素活性)与组合(所有剂量,P = .003和P <.001)和奈必洛尔(两者,P <。)联合治疗后24小时收缩压和舒张压降低8周相关。 001),但不能使用缬沙坦。仅在联合治疗后,基线ln(醛固酮)与24小时收缩压和舒张压降低相关(P <.001和P = .005)。这种β-受体阻滞剂-血管紧张素受体阻滞剂组合对肾素-血管紧张素-醛固酮系统作用的影响应进一步探讨。 (C)2015作者。由Elsevier Inc.代表美国高血压学会出版。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号